Study of IGC-AD1 in Subjects With Dementia Due to Alzheimer's Disease

Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
A single center, randomized, placebo controlled multiple ascending dose study of IGC AD1 to evaluate safety and tolerability in subjects with dementia due to Alzheimer\'s Disease (AD).
Epistemonikos ID: 0d91a25eff9b51b9e4e148677f40fc20e64a06d4
First added on: May 08, 2024